The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.75
Bid: 40.00
Ask: 41.50
Change: 0.25 (0.62%)
Spread: 1.50 (3.75%)
Open: 40.20
High: 40.75
Low: 40.20
Prev. Close: 40.50
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

14 Nov 2016 07:00

RNS Number : 0382P
Venture Life Group PLC
14 November 2016
 

Venture Life Group plc

("Venture Life" or the "Group")

 

Trading Update

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, provides the following trading update for the year ending 31 December 2016.

 

As stated at the time of the interim results on 21 September 2016, the strong revenue growth that we saw in the first half has continued into the second half of the year with the strong order book and strengthening Euro converting into improving revenue. As a result of the continued growth, the Group expects to report revenue for the year ending 31 December 2016 of not less than £14.0 million, an increase of more than 50% on Group revenue reported for the year ended 31 December 2015.

 

UltraDEX acquisition and performance

The Group has made good progress on the integration of Periproducts since the acquisition of the company and the UltraDEX brand in March 2016. Manufacturing processes for the UltraDEX toothpaste and oral rinse products have been fully established at the Group's manufacturing facility in Italy and the first UltraDEX products manufactured in-house have been shipped to customers. The leasehold property previously occupied by Periproducts in Ruislip has now been vacated and all operations transferred to Venture Life's offices in Bracknell.

 

The UltraDEX advertising campaign which launched on 10 October 2016 ran as planned for two weeks and the product sampling activity at certain London railway stations was well-received by consumers. As previously announced, the planned advertising campaign had led to a number of major UK retailers planning to increase store distribution and product listings for UltraDEX in Q4 2016. The Group saw an uplift in UltraDEX revenue compared to preceding months, in both September, resulting from these extra listings, and also during October, when there were both increased listings and the advertising campaign running.

 

As previously announced, the Group has signed three long term international distribution agreements for the UltraDEX range, and the first of these partners to launch the product in market is Serra Pamies in Spain. Serra Pamies initiated the launch during October 2016 with product manufactured at our Development & Manufacturing business. Malaysia will be the next market to launch UltraDEX in January 2017 and the product is currently in production.

 

UK Sales Director appointed

Tim Scott joined Venture Life on 4 November 2016 as the Group's new UK Sales Director. Tim has extensive experience of the health and beauty sector, having previously worked within the oral care division at GSK as well as for Sleek Cosmetics, acquired in 2015 by the Walgreens Boots Alliance Group. Tim will be responsible for developing our key account strategy and sales of our branded products into the UK market. Initially this will be focused on the UltraDEX range but we expect the scope to be widened to include bringing more of the Group's branded products to the UK market.

 

Other Commercial Activities

We continue to seek to partner our products globally, and have interest from many countries in our portfolio of products, including the new UltraDEX brand.

 

Our Development & Manufacturing business continues to grow and the Group expects 2016 to be a record year for revenue for this business. As part of our ambitious plans to grow the Group, we continue to invest in the Development & Manufacturing business to accommodate our growth plans and ensure that we remain competitive in quality, service and price.

 

The order book for 2017 is already building steadily and we are pleased to report that the order book for our Development & Manufacturing business for the month of January 2017 is already 45% higher than actual revenue recognised in January 2016, excluding intercompany sales.

 

Jerry Randall, CEO of Venture Life, commented: "The strong revenue growth this year is further evidence that the Group is on a trajectory towards achieving its strategic goal of becoming sustainably profitable. I am particularly pleased that we have now fully integrated the UltraDEX business into the Group and that we already have international partners preparing to launch the UltraDEX brand in overseas markets. I am delighted to welcome Tim Scott into the Group, to grow our UK presence with key retailers, initially with our UltraDEX product range. The strong Development & Manufacturing order book for January 2017, which is well ahead of actual January 2016 revenue, demonstrates that the momentum is continuing into 2017."

 

For further information please contact:

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

 

James Hunter, Chief Financial Officer

 

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope/Ben Turner

 

 

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Paul McManus/Anna Dunphy

+44 (0) 7980 541 994 / +44 (0) 7876 741 001

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

About Venture Life (www.venture-life.com)

 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

 

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its Development & Manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAKNDNBBDBFDD
Date   Source Headline
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results
25th Mar 20207:00 amRNSNotice of Results Update and Trading Update
9th Mar 20207:00 amRNSTrading Update and Notice of Results
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Jan 202012:37 pmRNSCompletion of Acquisition
9th Jan 20204:28 pmRNSDirector/PDMR Shareholding
6th Jan 20203:38 pmRNSGrant of Options
19th Dec 20197:00 amRNSAcquisition and Trading Update
18th Nov 20192:02 pmRNSHolding(s) in Company
11th Nov 201911:33 amRNSUltraDEX wins at the Dental Industry Awards 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.